O Brien Greene & Co. Inc Invests $206,000 in Cencora, Inc. (NYSE:COR)

O Brien Greene & Co. Inc acquired a new position in shares of Cencora, Inc. (NYSE:COR) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 913 shares of the company’s stock, valued at approximately $206,000.

A number of other large investors have also recently bought and sold shares of the business. Kingswood Wealth Advisors LLC bought a new stake in shares of Cencora in the 2nd quarter worth approximately $655,000. TD Asset Management Inc bought a new stake in Cencora in the first quarter valued at $95,313,000. LSV Asset Management acquired a new position in shares of Cencora during the first quarter valued at $3,579,000. Cairn Investment Group Inc. bought a new position in shares of Cencora during the first quarter worth about $2,294,000. Finally, Lake Street Advisors Group LLC acquired a new stake in shares of Cencora in the 1st quarter worth about $836,000. Institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. StockNews.com raised shares of Cencora from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. lifted their price target on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. Wells Fargo & Company boosted their price target on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. Leerink Partners restated an “outperform” rating and set a $275.00 price objective on shares of Cencora in a research report on Thursday, June 27th. Finally, Robert W. Baird lowered their price objective on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research note on Friday, September 6th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $258.13.

Insider Activity

In related news, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the sale, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the transaction, the insider now owns 19,980,000 shares of the company’s stock, valued at approximately $4,806,388,800. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,473 shares of Cencora stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the sale, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,450,399 shares of company stock worth $1,070,392,799. 15.80% of the stock is owned by corporate insiders.

Cencora Trading Down 2.8 %

NYSE:COR opened at $234.53 on Wednesday. The stock has a market cap of $46.78 billion, a PE ratio of 25.66, a price-to-earnings-growth ratio of 1.55 and a beta of 0.44. Cencora, Inc. has a fifty-two week low of $177.00 and a fifty-two week high of $247.66. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The stock’s 50-day moving average is $234.52 and its two-hundred day moving average is $233.26.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. The firm had revenue of $74.20 billion for the quarter, compared to the consensus estimate of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The firm’s revenue was up 10.8% on a year-over-year basis. During the same period in the previous year, the firm posted $2.92 earnings per share. As a group, equities research analysts forecast that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were given a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend was Friday, August 9th. Cencora’s payout ratio is presently 22.32%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.